Department of Health and Human Services, National Institutes of Health
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Who can apply
- County governments
- Independent school districts
- For-profit organizations (not small businesses)
- Special district governments
- Nonprofits without 501(c)(3) status
- Small businesses
- Federally recognized tribal governments
- Public and state-controlled colleges
- State governments
- Others (see eligibility details)
- Public and tribal housing authorities
- City or township governments
- Tribal organizations
- Nonprofits with 501(c)(3) status
- Private colleges and universities
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this grant
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combination therapies; discovery activities such as high-throughput screening and hit optimization; and stand-alone clinical trials.
Topics
GrantCalendar is not affiliated with Department of Health and Human Services. Details can change, so confirm everything on the official listing before you apply. Spotted a mistake? Tell us.
Similar open grants
- Closes in 2 days
- Closes in 6 days
- Closes in 6 days
- Closes in 6 days
- Closes in 6 days
Get new grants every Monday
One short email with new grants and deadlines coming up in the next two weeks. Unsubscribe in one click.